Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q2 FY2025 Earnings Presentation
9 slides from Phibro Animal Health's earnings presentation, Feb 6, 2025
Slide 1: Phibro Animal Health Corporation Webcast and Conference Call
Phibro Animal Health Corporation Webcast and Conference Call February 6, 2025 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2025 Second Quarter Ended December 31, 2024 February 6, 2025 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or cur
Slide 3: Key Themes
Key Themes Continued Sales Strong Growth in FY2025 Full Year Momentum Animal Health Guidance (Including Zoetis MFA) Q2 Total Consolidated sales and Q2 Total Animal Health sales 2025 guidance adjusted EBITDA growth of 24% and adjusted EBITDA growth of • Net sales of $1.250 and 64% 33% and 48% billion
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated Second Quarter, Year-on-Year comparison $ in millions, except per share data Q2 Q2 YOY FY24 FY25 %∆ Consolidated Net Sales $ 249.9 $ 309.3 24% Net Income $ 1.3 $ 3.2 150% Diluted EPS $ 0.03 $ 0.08 149% Adjusted EBITDA $ 29.5 $ 48.2 64% Adjusted Net Income $ 13.5
Slide 5: Financial Performance – Animal Health Legacy vs. New MFA
Financial Performance – Animal Health Legacy vs. New MFA Second Quarter, Year-on-Year comparison $ in millions Q2 Q2 FY25 YOY Q2 FY25 Q2 FY25 YOY FY24 Legacy %∆ New MFA Total %∆ Animal Health Net Sales $ 173.1 $ 192.7 11% $ 36.7 $ 229.4 33% MFAs & other 101.9 113.6 11% 36.7 150.3 47% Nutritional spe
Slide 6: Financial Performance – Other Segments
Financial Performance – Other Segments Second Quarter, Year-on-Year comparison $ in millions Q2 Q2 YOY FY24 FY25 %∆ Mineral Nutrition Net Sales $ 61.3 $ 63.3 3% Adj. EBITDA $ 3.5 $ 5.7 63% Adj. EBITDA Margin 5.7% 9.0% +330 bps Performance Products Net Sales $ 15.5 $ 16.6 7% Adj. EBITDA $ 0.8 $ 1.9 1
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics December 31, 2024 Free cash flow was $15 million for the TTM -- positive cash from operating activities of $55 million, less capital expenditures of $(40) million. Free Cash Flow (1) Cash and cash equivalents of $67 million 3.1x gross leverage ratio; $760 million total deb
Slide 8: Financial Guidance – Phibro
Financial Guidance – Phibro Fiscal Year 2025 $ in millions, except earnings per share (EPS) data FY 2024 FY 2025 FY 2025 Previous Legacy Only Updated Includes Zoetis Actual Low High Low High Consolidated Net Sales $ 1,018 $ 1,050 $ 1,100 $ 1,250 $ 1,300 Net Income $ 2 $ 36 $ 42 $ 39 $ 45 Diluted EPS
Slide 9: PAHC Company Overview Q&A
PAHC Company Overview Q&A 9 February 6, 2025 Webcast and Conference Call
Phibro Animal Health — Q2 FY2025 Earnings Presentation on 6ix